Enzymatic Wound Debridement Market (2026 - 2033)

Enzymatic Wound Debridement Market Summary

The global enzymatic wound debridement market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.2 billion in 2026 to USD 2.0 billion by 2033, at a CAGR of 7.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 45.0% in 2025. The market demand is rising owing to an increase in the prevalence of chronic diseases such as diabetes, cancer, and other autoimmune diseases, a high number of accidents, and the introduction of technologically advanced products across the globe.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamics

Analyst Perspective

The market is evolving as healthcare providers place greater emphasis on effective wound management while minimizing the need for invasive procedures. The treatment’s long-term potential lies in its ability to manage chronic, hard-to-heal wounds, which can significantly increase healthcare costs when prolonged care is required. Hospitals and wound care centers are increasingly evaluating products based on their impact on healing outcomes, treatment time, and overall resource utilization rather than solely on product cost. Companies with strong clinical evidence, established relationships with healthcare providers, and expertise in wound care are likely to strengthen their market position. As healthcare systems continue to focus on improving patient outcomes and reducing the burden of chronic wound management, demand is expected to favor solutions that can simplify treatment pathways and support more consistent healing results.

Type Insights

The acute wounds segment dominated the market in 2025. They include burns, abrasions, lacerations, incisions, and puncture wounds. An increase in burn injuries worldwide is a major factor driving segment growth. Every year, around 50% of the global population is at risk of fire-related trauma, of which 90.0% of cases occur in moderate- and low-income countries. As per the WHO, annually, there are over 1,000,000 reported cases of moderate or severe burns in India. Thus, the segment is expected to grow rapidly over the forecast period.

The chronic wounds segment is anticipated to witness the fastest growth over the forecast period. Chronic wounds include diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The pressure ulcers segment, along with other chronic wounds, is anticipated to grow the fastest over the forecast period. Pressure ulcers, also known as bed sores, usually occur due to prolonged, intense pressure on the skin.

Prolonged hospital stay is the most common cause of such ulcers. They are common in the geriatric population and typically occur in bony areas, such as the ankles, hips, and tailbone. The rising geriatric population worldwide is a major factor driving segment growth. Moreover, increases in the number of surgeries and in the prevalence of diseases requiring prolonged hospital stays are among the factors expected to drive segment growth in the coming years.

Product Insights

The collagenase-based segment held the dominant share in the global market for enzymatic wound debridement products. Collagenase-based ointments, creams, and gels are enzymatic debridement products used to remove necrotic tissue from venous leg ulcers, pressure ulcers, burn wounds, & partial-thickness burns. These products promote rapid healing and are also effective in treating diabetic foot ulcers.

Collagenase-based enzymatic wound debridement products are easily available and are commonly used by medical professionals. The rising prevalence of pressure ulcers, diabetic foot ulcers, and venous leg ulcers is anticipated to drive segment growth. These ulcers mainly occur over the heels or sacrum. In addition, according to NCBI, venous leg ulcers are common worldwide, especially in the U.S. and Northern Europe. Therefore, this segment is expected to grow significantly over the forecast period. Collagenase SANTYL ointment is one of the most used enzyme debridement products offered by Smith & Nephew.

The papain product segment is expected to register significant growth during the forecast period, driven by its ability to selectively remove necrotic tissue, promote wound bed preparation, and support the healing of chronic and hard-to-heal wounds. Papain-based enzymatic debridement products are increasingly used in the management of diabetic foot ulcers, pressure ulcers, venous leg ulcers, and burn wounds due to their non-surgical, cost-effective approach. The growing prevalence of chronic diseases, the rising incidence of diabetic wounds, and the increasing demand for advanced wound care solutions are further supporting segment growth.

In addition, ongoing research and development activities focused on next-generation enzymatic debridement therapies are expected to expand clinical adoption. For instance, in March 2025, SolasCure enrolled the first patient in its Phase II CLEANVLU2 clinical trial for Aurase Wound Gel, an enzymatic wound debridement therapy designed to improve chronic wound-healing outcomes, highlighting continued innovation in the enzymatic debridement market.

End Use Insights

The hospital segment held the largest market share of over 50.0% in 2025, attributed to the rising incidence of chronic wounds globally. Moreover, increasing cases of diabetic foot ulcers and venous leg ulcers are major drivers of segment growth. Moreover, the rising incidence of surgical wounds, driven by increased surgeries, is also boosting segment expansion. Enzymatic wound debridement is also used for healing surgical site infections. Thus, these factors may fuel segment growth over the forecast period.

The homecare segment is expected to grow at the fastest rate over the forecast period. Most surgeries require a prolonged recovery period, leading to frequent changes of dressings. Thus, the demand for wound debridement products in home healthcare settings is increasing. Moreover, the geriatric & bariatric population, as well as patients suffering from chronic wounds, prefer homecare over hospital stay.

Regional Insights

North America led the market, accounting for the highest revenue share of around 45.0% in 2025. An increase in the prevalence of sports injuries & road accidents, along with the presence of several key players, are factors anticipated to drive the market in North America. In addition, the availability of skilled professionals and improvements in healthcare infrastructure are expected to drive market growth over the forecast period. The U.S. held the dominant share of revenue in North America.

To learn more about this report, Download Free Sample Report

Asia Pacific Enzymatic Wound Debridement Market Trends

The enzymatic wound debridement market in the Asia Pacific is anticipated to grow the fastest over the forecast period. The rising incidence of chronic wounds, such as diabetic ulcers and pressure ulcers, in the aging population of the region is likely to fuel the demand for advanced wound care solutions such as enzymatic debridement. Increasing healthcare expenditure in countries such as China, India, Japan, and Australia is driving the regional adoption of advanced wound care techniques and improving healthcare facilities and infrastructure.

Key Enzymatic Wound Debridement Company Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and expand their global reach.

• In May 2025, MediWound reported positive progress in the clinical development of EscharEx, its enzymatic debridement therapy for chronic wounds, including the initiation of the global Phase III VALUE trial for venous leg ulcers. The advancement strengthens the company’s market position and supports the development of next-generation solutions for chronic wound management.

• In February 2025, MediWound initiated the global Phase III VALUE trial for EscharEx, its investigational enzymatic debridement therapy for venous leg ulcers. The study is designed to evaluate the efficacy and safety of EscharEx in chronic wound debridement. It represents a significant advancement in the development of next-generation enzymatic wound care solutions.

Key Enzymatic Wound Debridement Companies

The following key companies have been profiled for this study on the enzymatic wound debridement market:

• Convatec Inc.

• Smith & Nephew

• Mölnlycke Health Care AB

• Integra LifeSciences

• SOLASCURE Limited

• B. Braun

• MediWound Ltd.

• Organogenesis Holdings Inc.

• Coloplast A/S

• PAUL HARTMANN AG

Global Enzymatic Wound Debridement Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global enzymatic wound debridement market report based on type, product, end use, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Chronic Wounds

    • Diabetic Foot Ulcers

    • Pressure Ulcers

    • Venous Leg Ulcers

  • Acute Wounds

    • Burn

    • Other Acute Wounds

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Collagenase Product

  • Papain Product

  • Others

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals

  • Homecare

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait